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OBJECTIVES: The present study was designed to evaluate the bone phenotypes and mechanisms involved in
bone disorders associated with hepatic osteodystrophy. Hepatocellular disease was induced by carbon tetra-
chloride (CCl4). In addition, the effects of disodium pamidronate on bone tissue were evaluated.
METHODS: The study included 4 groups of 15 mice: a) C = mice subjected to vehicle injections; b) C+P = mice
subjected to vehicle and pamidronate injections; c) CCl4+V = mice subjected to CCl4 and vehicle injections; and
d) CCl4+P = mice subjected to CCl4 and pamidronate injections. CCl4 or vehicle was administered for 8 weeks, while
pamidronate or vehicle was injected at the end of the fourth week. Bone histomorphometry and biomechanical
analysis were performed in tibiae, while femora were used for micro-computed tomography and gene expression.
RESULTS: CCl4 mice exhibited decreased bone volume/trabecular volume and trabecular numbers, as well as
increased trabecular separation, as determined by bone histomorphometry and micro-computed tomography,
but these changes were not detected in the group treated with pamidronate. CCl4 mice showed increased
numbers of osteoclasts and resorption surface. High serum levels of receptor activator of nuclear factor-kB
ligand and the increased expression of tartrate-resistant acid phosphatase in the bones of CCl4 mice supported
the enhancement of bone resorption in these mice.
CONCLUSION: Taken together, these results suggest that bone resorption is the main mechanism of bone loss in
chronic hepatocellular disease in mice.
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’ INTRODUCTION
The liver is a multifunctional organ that occupies a key
position in the modulation of carbohydrate, protein, and
lipid metabolism. At the same time, it plays a critical role
in mineral metabolism and growth. As expected, chronic
hepatic disorders are included in the list of diseases con-
sidered to be potential causes of osteoporosis (1). Hepatic
osteodystrophy (HOD) is the generic name for the hetero-
geneous bone diseases associated with chronic liver disease,
and, HOD combines components of osteoporosis and osteo-
malacia (2, 3).
In the literature, there has been a convergence of evidence
suggesting that bone loss is the primordial bone disorder
during the early stages of hepatic disease (4). Vitamin D
deficiency appears later, with osteomalacia being an advanced
manifestation (5). Disagreement persists regarding the pat-
tern of bone loss. Some studies have shown that decreased
bone formation is the predominant impairment in bone
remodeling (6), while others have shown that increased bone
resorption is the main cause of bone loss in HOD (7).
Moreover, cholestasis could be an additional componentDOI: 10.6061/clinics/2017(04)07
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that may contribute to the differences between previously
obtained results (8, 9).
Cross-sectional (10) and longitudinal (11) clinical studies
have shown that cholestasis impairs bone mass development
in children and adolescents with non-severe cholestatic
disease. In these studies, the serum levels of endocrine IGF-I
were reduced. The importance of endocrine and autocrine/
paracrine IGF-I, as well as reduced bone formation, for the
generation of osteopenia in cholestasis was also emphasized
in rats subjected to bile duct ligation (12). In addition to the
reduction of bone volume (BV/TV), these animals exhibited
low serum levels of IGF-I and decreased expression of growth
hormone receptors and IGF-I in bone (12). In these studies,
there were no indications of increased bone turnover or osteo-
clast activity, but a lower rate of mineral apposition indicated
low osteoblastic activity (12).
Bisphosphonates, including disodium pamidronate, are
analogs of inorganic pyrophosphates that exhibit carbon
linked to phosphate (P-C-P) instead of to oxygen. The main
pharmacological effect of bisphosphonates is that they
inhibit bone resorption. Previous experimental and clinical
studies have shown the benefits of pamidronate treatment
in HOD (2).
The present study was designed to evaluate the mechan-
isms involved in the emergence of HOD in non-cholestatic
liver disease. A pharmacological model of cirrhosis was
used, with C57BL/6 mice subjected to the administration of
carbon tetrachloride (CCl4). The effects of disodium pami-
dronate on bone were also evaluated. Bone remodeling and
microstructure were assessed by histomorphometry in tibiae
and by micro-computed tomography (micro-CT) in femora,
respectively. There are no data in the literature concerning
the expression of genes directly or indirectly involved in
bone formation and bone resorption in the bones of cirrhotic
mice. Therefore, the final target of the present study was to
evaluate the gene expression of RUNX-2, receptor activator
of nuclear factor-kB ligand (RANKL), osteoprotegerin (OPG)
(Applied Biosystems, Foster City, CA, USA), and tartrate-resistant
acid phosphatase (TRAP) in the bones of control and cirrhotic
mice submitted or not to disodium pamidronate therapy.
’ MATERIALS AND METHODS
The experimental protocol was approved by the Institu-
tional Animal Care and Use Committee of the Ribeirão Preto
Medical School, University of São Paulo (protocol no. 111/
2011). The animal experiments were performed in strict
accordance with international guidelines, as recommended
in the Guide for the Care and Use of Laboratory Animals of
the Ribeirão Preto Medical School, USP, Animal Research
Committee. The mice were divided into 4 groups of 15 ani-
mals each as follows: a) C = mice received intraperitoneal
(IP) injections of vehicle for 8 weeks and one IP injection of
saline solution at the end of the fourth week; b) C+P = mice
received IP injections of vehicle and one IP injection of
disodium pamidronate; c) CCl4 = mice received IP injections
of CCl4 for 8 weeks and one IP injection of saline solution;
and d) CCl4+P = mice received, twice per week, IP injec-
tions of CCl4 for 8 weeks and one IP injection of disodium
pamidronate at the end of the fourth week. The clinical
conditions of the animals were routinely evaluated once per
day in the morning to avoid unnecessary additional stress.
There was a mortality rate of 25% in the groups of mice
subjected to the IP injection of CCl4, and this rate was not
influenced by the additional administration of disodium
pamidronate.
The central animal facility of the Ribeirão Preto Medical
School, USP, provided all of the animals used during the
study. Five-week-old male mice weighing approximately 18 g
were housed in cages in a room with controlled humidity
and temperature (23±1oC) conditions and with an artificial
light/dark cycle of 12 hours (lights on: 06:00 AM-06:00 PM).
The animals had free access to tap water and pellet chow.
To induce the cirrhosis model, the mice were treated with
CCl4 (1 mL/kg body weight) dissolved in olive oil 1:4 (v:v)
administered by intraperitoneal injection twice per week,
as adapted from previous studies in this line of investiga-
tion (13, 14). At the end of the 8-week period of CCl4 injec-
tion, a two-week interval was allowed to elapse to allow
for the consolidation of hepatic disease. Mice in the C+P
and CCl4+P groups were treated with an IP injection
of disodium pamidronate (Eurofarma, Ribeirão Preto, SP,
Brazil) dissolved in 0.9% NaCl at 1.25 mg/kg at the end
of the fourth week (15). At the end of the tenth week, the mice
were sacrificed by cervical dislocation, and the blood was
immediately collected.
Biochemical assessment
Serum samples were stored after the end of the experi-
mental protocol for future determinations. Aspartate tran-
saminase (AST) and alanine transaminase (ALT) activities
were measured by colorimetry (Labtest, Lagoa Santa, MG,
Brazil) with a spectrophotometer (SpectraMax M-5, Mole-
cular Devices, Biocompare, San Francisco, CA, USA). RANKL
and OPG were determined by ELISA, as indicated by the
manufacturer (R&D Systems, USA). The intra-assay coeffi-
cients of variation were 7.2% and 5.3% for RANKL and OPG,
respectively.
Image evaluation
The left femora were scanned using a micro-CT instrument
(1172; SkyScan, Kontisch, Belgium), as previously described
(16). The trabecular bone volume fraction and micro-
architecture of the secondary spongiosa were assessed in the
distal portion of the right femora starting at 0.25 mm
proximal to the distal growth plate and covering proximally
a total length of 1 mm. The bones were scanned at low
resolution, with an energy level of 55 kVp and intensity of
145 mA. The equipment underwent a weekly programmed
calibration with phantoms presenting with densities of
0.25 and 0.75 mg/cm3. The CT-analyzer software, version
1.13.2.1, was used for quantitative assessment. The results
are expressed according to standardized nomenclature (17).
Bone histomorphometry
Quantitative static histomorphometry was performed as pre-
viously described (12). In brief, the tibiae were removed and
dehydrated in ethanol, infiltrated, and embedded in methyl
methacrylate without demineralization. Undecalcified sec-
tions were cut at a thickness of 5 mm and were stained with
0.1% toluidine blue. Histomorphometric assessment was
performed on the secondary spongiosa of the proximal tibia
metaphysis using an OsteoMeasure morphometry system
(Osteometrics, Atlanta, GA, USA). The histomorphometric
indexes were as follows: bone volume (BV/TV, %), osteoid
volume (OV/BV, %), osteoblast surface (Ob.S/BS, %),
osteoclast surface (Oc.S/BS), osteoid surface (OS/BS, %),
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eroded surface (ES/BS, %), trabecular separation (Tb.Sp, mm),
trabecular number (Tb.N, /mm), and trabecular thickness
(Tb.Th, mm).
RNA isolation and quantitative real-time PCR
Total femoral RNA was prepared using a standard TRIzol
(Sigma-Aldrich) method, according to the manufacturer’s
instructions. RNA quantity and purity were assessed using
a nanophotometer, and a sample with an A260/A280 ratio
of 1.9 - 2.1 was used in the present study. cDNA was gener-
ated from 1 mg of total RNA using a reverse transcriptase
kit (Pre-Improm II, Promega, Madison, WI, USA), accord-
ing to the manufacturer’s instructions. Subsequently, cDNA
was used to assess mRNA expression using the TaqMan Fast
Advanced Master Mix kit (Applied Biosystems, Foster City,
CA, USA) with a thermal cycler StepOnePlust Real Time
PCR System (Applied Biosystems, Foster City, CA, USA).
Relative mRNA expression was determined after normaliza-
tion for b-actin. RANKL (Mm00441906), OPG (Mm01205928),
RUNX-2 (Mm00501584_m1), and TRAP (Mm00475698_m1)
inventoried primers were purchased from Applied Biosys-
tems. The expression of target genes was determined by the
threshold cycle (CT) values of each sample, which were
normalized to the housekeeping genes (2-DCT).
Biomechanical testing
Frozen left tibiae were thawed at room temperature for
2 h before testing. Mechanical resistance was assessed on
intact tibiae using a destructive three-point bending proce-
dure. Bones were positioned supine on two round bars
separated by a distance of 15 mm in a mechanical testing
machine (10,000 N, EMIC DL, São José dos Pinhais, PR,
Brazil) and were deflected by a notched bar on the opposite
side of the bone. The descending speed of the notched bar
was 1 mm/min. Maximal force was determined from force/
deflection plots.
Statistical analysis
The results obtained for the four groups were compared
using a Kruskal-Wallis one-way analysis of variance fol-
lowed by Dunn’s post-test. Additionally, Spearman’s test
was used to determine the correlation between two para-
meters. The statistical analysis was performed using Graph-
Pad Instat software, version 5.0. Differences were accepted
as significant at po0.05.
’ RESULTS
Body weight gain and mouse final weight were not signif-
icantly different between the groups (Table 1). In addition,
the liver weights of the CCl4 and CCl4+P groups were sig-
nificantly higher than those of the C and C+P groups
(po0.05; Table 1).
All of the mice injected with CCl4 developed hepatic
cirrhosis, which was confirmed by the structural derange-
ments of liver parenchyma in the anatomopathological exam
(data not shown), as well as by biochemical changes (Table 1).
The mice in the CCl4 and CCl4+P groups showed higher
serum levels of ALT and AST than the other two groups
(Table 1). In addition, there was no difference in serum levels
of ALT or AST between the two group pairs, i.e., C vs C+P
and CCl4 vs CCl4+P.
The serum levels of RANKL were significantly higher in
the CCl4 group (0.087±0.01 pg/mL) than in the C group
(0.059±0.02 pg/mL) (po0.05). The cirrhotic group treated
with pamidronate (CCl4+P = 0.047±0.01) showed serum
levels of RANKL similar to those in the control group. The
circulatory rates of OPG in the four groups were not
significantly different (C = 9.88±4.6 vs C+P = 6.2±3.0 vs
CCl4 = 7.52±2.7 vs CCl4+P = 6.0±3.7 pg/mL).
Table 2 shows the structural characteristics of femoral
trabecular bone as evaluated by mCT from the four groups of
mice. The CCl4 group exhibited lower BV/TV and Tb.N
values and higher Tb.Sp values than the C+P group. The
CCl4+P group showed improved BV/TV, Tb.N, and Tb.Sp
values compared with the CCl4 group. The trabecular micro-
structure of the CCl4+P group did not differ from that of
the C and C+P groups.
Consistent with the results obtained with femoral micro-
CT, a bone histomorphometric assessment of the tibiae
showed lower values of BV/TV and Tb.N and higher values
of Tb.Sp in the CCl4 group than in the C+P group (Table 3).
In addition, the CCl4 group exhibited higher Oc.S/BS and
Table 1 - Clinical and biochemical phenotypes.
C C+P CCl4 CCl4+P
Weight (g) 29.0±1.4 28.7±3.5 29.1±1.7 26.7±2.8
Liver weight (mg/g) 51.3±4.6 47.8±3.0 56.4±5.4* 59.6±3.6**
ALT (U/L) 47.9±7.2 43.3±27.8 137.7±33.3* 133.9±22.9**
AST (U/L) 32.3±16.2 36.9±37.3 155.8±19.6* 168.8±17.8**
RANKL(pg/mL) 0.059±0.02 0.061±0.02 0.087±0.01+ 0.047±0.01++
OPG (pg/mL) 9.88±4.6 6.2±3.0 7.52±2.7 6.0±3.7
*4 C and C+P; **4 C and C+P; +4 C; ++o CCl4; po0.05
ALT: alanine transaminase; AST: aspartate transaminase; RANKL: receptor activator of nuclear factor-kB ligand; and OPG: osteoprotegerin.
Table 2 - Micro-CT assessment in the femora of the four groups.
C (n=6) C + P (n=6) CCl4 (n=6) CCl4 + P (n=6)
BV/TV (%) 11.96±3.47 17.22±3.07 10.40±3.53* 12.89±4.44
Tb.Th (mm) 0.054±0.009 0.053±0.002 0.054±0.008 0.047±0.005
Tb.N (1/mm) 2.28±0.28 3.24±0.54 1.67±0.13* 2.25±0.70
Tb.Sp (mm) 0.17±0.02 0.089±0.009+ 0.22±0.02** 0.10±0.01++
*o C+P; **4 C+P; +o C; ++o CCl4; po0.05
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ES/BS values than did the C+P group, whereas the CCl4+P
group showed lower Oc.S/BS and ES/BS values than the
CCl4 group.
In bone, the expression of RANKL and OPG, as well as
the RANKL/OPG ratio, was not significantly higher in the
CCl4 group than in the C group. The expression of TRAP
was higher in the CCl4 group than in the C and C+P groups.
The expression of RUNX-2 was significantly higher in bone
from the CCl4+P group than in bone from the other three
groups (Figure 1).
The force needed to fracture the tibiae was significantly
lower in the CCl4 group (10.5±3.2 N) than in the C group
(14.7±1.7 N) (po0.05; Figure 1). The figure also shows that
pamidronate treatment efficiently improved bone resistance
in cirrhotic mice. The force needed to fracture bone in
the CCl4+P group (13.1±3.2 N) was similar to that in the
C group but was lower than that in the C+P group (17.3±
2.1 N) (Figure 2).
’ DISCUSSION
Bone remodeling is a crucial process that enables the skel-
eton to reconcile two apparently paradoxical properties,
i.e., lightness and strength. The sequential activities of bone
resorption and formation, when limited to areas with pre-
existing micro-damage, allow the hard tissue to renew itself,
Table 3 - Bone histomorphometry in the tibiae of the four groups.
C (n=7) C + P (n=6) CCl4 (n=7) CCl4 + P (n=7)
BV/TV (%) 10.4±2.9 12.6±2.1 7.9±1.4* 10.6±3.4
OV/BV (%) 1.84±1.42 2.39±0.42 1.32±0.77 2.74±1.46
Tb.Th (lm) 49.0±5.3 54.3±9.1 56.7±16.6 46.8±9.8
Tb.N (/mm) 2.1±0.3 2.3±0.3 1.4±02* 2.2±0.3+
Tb.Sp (lm) 439.1±95.4 376.9±58.3 657.7±149.7** 410±80.2++
Oc.S/BS (%) 1.4±0.9 0.2±0.3 2.8±2.2** 0.5±0.6++
ES/BS (%) 1.6±0.6 0.3±0.4 4.6±2.4** 0.9±0.7++
Ob.S/BS (%) 7.3±3.4 8.4±2.6 7.0±4.6 7.7±3.1
OS/BS (%) 18.9±9.7 23.08±6.5 14.79±5.2 19.4±7.1
*o C+P; **4 C+P; +4 CCl4; ++o CCl4; po0.05
Figure 1 - Bone mRNA levels of RANKL, osteoprotegerin, RUNX-2, and TRAP in the four groups (C, C+P, CCl4, and CCl4+P). All
expression levels are presented relative to b-actin expression (RT-PCR). N=6 per genotype.* CCl4+P4 C, C+P, and CCl4; ** CCl44 C and
C+P, po0.05.
Figure 2 - Maximum force attained in the four groups (C, C+P,
CCl4, and CCl4+P).* CCl4 o C, C+P, and ** CCl4+P o C+P,
po0.05.
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preventing the emergence of bone fragility. The equilib-
rium of these interdependent activities is complex, involving
a close interaction of genetic, nutritional, hormonal, neural,
and environmental factors. A deleterious imbalance can result
from the excessive activation of osteoclasts or impairment of
osteoblast activity. Disease- and drug-induced osteoporosis
are associated with one of these two mechanisms or their
combination. For example, in glucocorticoid-induced osteo-
porosis, two distinct phases were identified (18). In the first
phase, increased osteoclast resorption prevails, whereas after
six months, osteoblast and osteocyte dysfunction predomina-
tes. Therefore, in heterogeneous diseases, it can be presumed
that either mechanism may exist, depending on the cir-
cumstances. Corroborating previous studies that showed
the impact of chronic hepatic disorder on the skeleton, the
present study contributes to advancements in this line of
investigation. Based on the previous experience of our group
in the study of bone disturbances in cholestasis (clinical and
experimental) (10-12, 19), we observed conspicuous differ-
ences in bone remodeling using an experimental model of
cirrhosis. While the predominant bone impairment seems to
be low osteoblastic activity in cholestasis, in hepatocellular
disease, increased osteoclastic action appears to be the major
mechanism of bone loss. This hypothesis was substantiated
by histomorphometric analysis (i.e., increased Oc.S/BS in
the CCl4 group, while there was no difference in Ob.S/BS
between groups) and by biochemical markers of bone
remodeling and gene expression in bone.
Previous studies have emphasized that osteoporosis is a
major complication of chronic hepatic diseases. Additionally,
it is well accepted that the prevalence and severity of bone
loss are increased in cholestasis (2). In a previous cross-
sectional study, we demonstrated that children with congenital
cholestasis had low bone mass (10). In another longitudinal
study, we documented impairment of bone mass acquisi-
tion (11). In these studies, the serum levels of PTH and
25-hydroxyvitamin D were normal, whereas decreased IGF-I
was an early biochemical change in cholestasis (10, 11). Bone
loss was an early event in hepatic cholestasis, as 85% of the
children were classified as Child-Pugh A and the other 15%
were classified as Child-Pugh B. After 3 years, more consistent
incremental increases in the serum levels of osteocalcin were
observed in the control group (76%) than in children with
cholestasis (31%) (11). Moreover, Klein et al. (2002) reported
decreased serum levels of osteocalcin and type I collagen
telopeptide (ICTP) in children showing advanced cholestatic
liver disease (6). Disturbances in bone formation were also
observed in rats subjected to bile duct ligation (12). In contrast,
in a group predominantly consisting of patients with hepatic
liver disease, Crosbie et al. found that bone resorption was the
most important cause of bone loss in hepatic osteodystrophy
(5). Based on the present findings and previous reports, we
hypothesize that cholestatic and hepatocytic disease leads to
bone loss by diverse mechanisms. While the impairment of
bone formation is the hallmark of cholestatic disorders, bone
resorption prevails in hepatocytic diseases. Nevertheless, both
disorders are associated with osteoporosis. In the present
study, we detected decreased bone volume and trabecular
number, as well as increased trabecular separation, in the tibiae
and femora of mice with cirrhosis induced by CCl4. These
results agree with those recently obtained by Naussler et al.
(2014) (20). In addition, the present study demonstrated bone
weakness by biomechanical tests and showed that pami-
dronate efficiently reversed bone loss and improved bone
strength. The present study reinforced the positive effect of
disodium pamidronate on the skeleton, improving bone
mass as well as bone strength. It should be emphasized that
disodium pamidronate, an antiresorptive drug, not only
increased bone mass in diseases associated with increased
bone resorption but also improved bone mass in disorders
characterized by low bone formation.
RANKL, its cellular receptor RANK, and the decoy recep-
tor OPG are cytokines involved in the crosstalk between
osteoblasts and osteoclasts. RANKL produced by osteoblasts
dictates osteoclast differentiation and activity through RANK
activation in the membranes of osteoclast precursors. OPG
produced by osteoblasts deactivates RANKL, thus hamper-
ing osteoclastogenesis. In mice subjected to CCl4 injection,
the serum levels of RANKL were higher than those in the
control group. Additionally, pamidronate decreased the cir-
culatory levels of RANKL. These results are consistent with
data obtained in the ATP-binding cassette transporter B4
knockout mouse (Abcb4 / ), which is a well-established
experimental model of hepatic disease. In addition to the
compatible results regarding bone phenotypes obtained by
micro-CT analysis, the present study also revealed similar
results related to the serum levels of RANKL (21). In addi-
tion, our results showed that cirrhotic mice treated with
pamidronate had significantly lower serum levels of RANKL.
Moreover, we showed that RANKL expression in bone was
slightly increased in mice with hepatic osteodystrophy. The
increased expression of TRAP in bone was additional evi-
dence of enhanced osteoclast action in the bones of mice
exhibiting hepatic osteodystrophy. To the best of our knowl-
edge, the present study is the first to evaluate TRAP, a
marker of osteoclast expression, in bones from cirrhotic mice.
The increased expression of TRAP in the CCl4 group was
consistent with the higher numbers of osteoclasts on the
trabecular surface and the deteriorated bone structure of the
same group. Moreover, these results indirectly agreed with a
previous study showing higher levels of biochemical markers
of bone resorption in the serum of cirrhotic individuals, par-
ticularly in those with synthetic dysfunction (22).
Previous studies have shown contradictory results related
to the osteogenic effects of bisphosphonates. Bisphosphonates
are antiresorptive drugs; their metabolic and pro-apoptotic
effects strongly hamper osteoclast activity. However, their
effects on cells of osteoblastic lineages are far less well known.
There have been studies showing that bisphosphonates lead
to osteoblast apoptosis, inhibiting their differentiation (23).
In contrast, there has been evidence indicating that bispho-
sphonates induce osteoblastic proliferation and differentia-
tion (24-26). Furthermore, there are also data showing that
the effects of bisphosphonates on osteoblastogenesis are
dose-dependent (26). It was recently verified that bispho-
sphonate treatment shrinks bone marrow adipose tissue.
These data indirectly suggested a preferential commitment of
progenitor cells to differentiate into osteoblasts instead of
adipocytes (27). Previous in vitro studies have shown that
other bisphosphonates (i.e., zoledronate, ibandronate, and
clodronate) increased the expression of osteogenic genes,
including distal-less homeobox 5 (dlx5), RUNX2, the homeo-
box analogs known as melanocyte-stimulating hormone
(MSH) homeobox 1 and 2 (msx1 and msx2), and OCN (28).
Taken together, these data agree with our results showing a
significant increase in the bone expression of RUNX2, a key
transcription factor for osteoblast differentiation, in cirrhotic
mice treated with pamidronate. However, after disodium
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pamidronate treatment, the significant increase in the expres-
sion of RUNX2 in bone was restricted to animals treated with
CCl4. There is no clear explanation for this occurrence, but in
a previous study, it was observed that RUNX-2 expression
was elevated in the livers of cirrhotic mice previously treated
with CCl4 (29). The study called attention to RUNX-2 regu-
lating collagen synthesis, demonstrating that myofibroblasts,
including hepatic stellate cells and portal fibroblasts, express
RUNX-2 (29). This insightful study indicated that CCl4 could
up-regulate RUNX-2 in mesenchymal cells, unlike in oste-
oblasts (29). No previous study has evaluated the effects
of disodium pamidronate in mice previously indirectly
subjected to CCl4 by injection. The present study encourages
further studies to address the mechanism of action of diso-
dium pamidronate in HOD.
This study has some limitations. The dynamic parameters
of bone histomorphometry were not evaluated. However,
the present findings are important preliminary data for a
more comprehensive study examining alterations in bone
remodeling, namely, increased bone resorption as the main
mechanism of bone loss in cirrhosis predominantly due to
hepatocyte disorders.
The present study showed that liver disease provoked by
CCl4-induced hepatocyte damage profoundly affected bone
microstructure and strength. Biochemical, molecular, and
histomorphometric evidence suggested that increased bone
resorption is the main mechanism involved in the process of
bone loss. Based on previous data obtained in our laboratory,
these results strikingly differed from bone disturbances
associated with hepatic cholestasis, which mainly presents
as changes in bone formation.
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